XXXX and @entity5591 improves protection against the lethal and incapacitating effects of nerve agent @entity4968 in the @entity840 .

@entity840 @entity4836 @entity12934 @entity4968 @entity12935 @entity4834 @entity2607 @entity5591 @entity204 @entity4835
This study is drawn from a work programme aimed at developing improved medical counter measures for nerve agent @entity4968 . @entity840 were administered @entity4836 (5.1 microg/h) or @entity2607 (4.7 microg/h) and @entity5591 (1.94 microg/h) for 6 days via a subcutaneously implanted mini osmotic pump. @entity4836 inhibited red cell @entity12935 ( @entity12935 ) by 44.2 +/- 2.7% and plasma cholinesterase (ChE) by 29.9 +/- 1.8%. @entity2607 and @entity5591 inhibited red cell @entity12935 by 18.7 +/- 3.7% and plasma ChE by 44.1 +/- 3.1%. On day 6, animals were challenged with a lethal dose of @entity12934 (GA; 125 microg/kg), @entity4834 (GB; 51.2 microg/kg), @entity4835 (GD; 31.2 microg/kg), GF (50 microg/kg) or VX (11.25 microg/kg) administered by the subcutaneous route. Animals were closely observed for signs of @entity4968 . The time to the onset of signs of @entity4968 was similar for all the agents except for VX, which showed a delay compared to the other agents. Following pretreatment with either @entity4836 or @entity2607 and @entity5591 most animals survived for 2-3 h following nerve agent administration. In contrast, only @entity2607 and @entity5591 prevented or reduced the duration of the signs of incapacitation and the temperature drop produced by all the agents. @entity4836 -pretreated animals showed little or no recovery from incapacitation prior to @entity204 . @entity2607 and @entity5591 pretreatment provided statistically (P < 0.05) better protection against GB, GD and VX lethality (24 h) than @entity4836 pretreatment and better protection against GA and GF lethality.
